diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM9374diaendo-9374Research ArticleОбзорыReviewФарнезоидный рецептор (FXR) как потенциальная терапевтическая мишень при неалкогольной жировой болезни печени и ассоциированных заболеванияхFarnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromeshttps://orcid.org/0000-0002-8664-6341БоголюбоваАполлинария ВасильевнаBogolyubovaApollinariya V.

младший научный сотрудник лаборатории передачи внутриклеточных сигналов в норме и патологии

junior research associate

apollinariya.bogolyubova@gmail.comhttps://orcid.org/0000-0001-5825-3287МайоровАлександр ЮрьевичMayorovAlexander Y.

д.м.н., заведующий отделом прогнозирования инноваций диабета

MD, PhD

education@endocrincentr.ruhttps://orcid.org/0000-0002-5371-8708МишинаЕкатерина ЕвгеньевнаMishinaEkaterina E.

аспирант, научный сотрудник

MD, PhD student, research associate

eka-mi@rambler.ruhttps://orcid.org/0000-0002-5958-5272ШварцАнтон МарковичSchwartzAnton M.

научный сотрудник лаборатории передачи внутриклеточных сигналов в норме и патологии

research associate

shvarec@yandex.ruhttps://orcid.org/0000-0002-8216-517XБелоусовПавел ВладимировичBelousovPavel V.

младший научный сотрудник лаборатории передачи внутриклеточных сигналов в норме и патологии

junior research associate

belousp@gmail.com<p>ФГБУН Институт молекулярной биологии им. В.А. Энгельгардта Российской академии наук</p>Россия<p>Engelhardt Institute of Molecular Biology</p>Russian Federation<p>ФГБУ Научный медицинский исследовательский центр эндокринологии Минздрава России</p>Россия<p>Endocrinology Research Centre</p>Russian Federation201717022018206449453Copyright &#x00A9; Боголюбова А.В., Майоров А.Ю., Мишина Е.Е., Шварц А.М., Белоусов П.В., 20172017Боголюбова А.В., Майоров А.Ю., Мишина Е.Е., Шварц А.М., Белоусов П.В.Bogolyubova A.V., Mayorov A.Y., Mishina E.E., Schwartz A.M., Belousov P.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/9374

Неалкогольная жировая болезнь печени (НАЖБП) представляет собой группу связанных с ожирением патологических изменений, характеризующихся аномальным накоплением липидов в клетках паренхимы печени. НАЖБП и различные ассоциированные с ней состояния, такие как резистентность к инсулину и сахарный диабет 2 типа (СД2), а также возможные риски развития фиброза и цирроза печени с потенциальным исходом в печеночно-клеточный рак представляют собой первостепенные проблемы здравоохранения в развитых странах, постепенно вытесняя по значимости аналогичные патологии, вызываемые регулярным употреблением гепатотоксических доз алкогольных напитков. Фундаментальные и клинические исследования последних лет продемонстрировали важную роль фарнезоидного рецептора (FXR, NR1H4) в регуляции метаболизма глюкозы, липидов и желчных кислот. Настоящий обзор посвящен молекулярным аспектам патогенеза НАЖБП, роли FXR (NR1H4) в биологии этого заболевания, а также перспективам использования различных (в том числе разнонаправленных) модуляторов действия FXR (NR1H4) для терапии НАЖБП и ассоциированных с ней состояний, таких как метаболический синдром и СД2, а также других заболеваний, в патогенезе которых играет роль FXR (NR1H4).

Nonalcoholic fatty liver disease (NAFLD) is a group of obesity-associated pathological changes characterized by abnormal accumulation of lipids in cells of the liver parenchyma. NAFLD and associated conditions, namely insulin resistance and type II diabetes mellitus (DM2), as well as the possible risks of developing fibrosis and cirrhosis with a potential outcome in hepatocellular carcinoma, represent the primary health problems in developed countries, gradually replacing the importance of similar pathologies caused by the regular use of hepatotoxic doses of alcoholic beverages. Recent fundamental and clinical studies demonstrated the important role of the farnesoid receptor (FXR, NR1H4) in the regulation of the metabolism of glucose, lipids and bile acids. This review focuses on the molecular aspects of the pathogenesis of NAFLD, the role of FXR (NR1H4) in the biology of this disease, and the prospects for using different FXR (NR1H4) modulators for therapy of NAFLD and associated conditions such as metabolic syndrome and DM2, as well as a number of other FXR (NR1H4) – mediated diseases.

неалкогольная жировая болезнь печенинеалкогольный стеатогепатитфарнезоидный рецепторnonalcoholic fatty liver diseasenonalcoholic steatohepatitisfarnesoid XОбзор литературы подготовлен в рамках реализации научной программы, поддержанной грантами Российского научного фонда: проекты №17-15-01475 (НАЖБП и ассоциированные состояния) и №16-15-10423 (FXR в клетках злокачественных опухолей).ReferencesBenedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9(16):715–732. doi: 10.4254/wjh.v9.i16.715Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9(16):715–732. doi: 10.4254/wjh.v9.i16.715Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20(2):205–214. doi: 10.1016/j.cld.2015.10.001Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20(2):205–214. doi: 10.1016/j.cld.2015.10.001Kanwar P, Kowdley KV. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clin Liver Dis. 2016;20(2):225–243. doi: 10.1016/j.cld.2015.10.002Kanwar P, Kowdley KV. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clin Liver Dis. 2016;20(2):225–243. doi: 10.1016/j.cld.2015.10.002Non-alcoholic Fatty Liver Disease Study Group; Lonardo A, Bellentani S, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006. doi: 10.1016/j.dld.2015.08.004Non-alcoholic Fatty Liver Disease Study Group; Lonardo A, Bellentani S, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006. doi: 10.1016/j.dld.2015.08.004Godos J, Federico A, Dallio M, Scazzina F. Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. International Int J Food Sci Nutr. 2017;68(1):18–27. doi: 10.1080/09637486.2016.1214239Godos J, Federico A, Dallio M, Scazzina F. Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. International Int J Food Sci Nutr. 2017;68(1):18–27. doi: 10.1080/09637486.2016.1214239Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103(10):3920–3925. doi: 10.1073/pnas.0509592103Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103(10):3920–3925. doi: 10.1073/pnas.0509592103Parséus A, Sommer N, Sommer F, et al. Microbiota-induced obesity requires farnesoid X receptor. Gut. 2017;66(3):429–437. doi: 10.1136/gutjnl-2015-310283Parséus A, Sommer N, Sommer F, et al. Microbiota-induced obesity requires farnesoid X receptor. Gut. 2017;66(3):429–437. doi: 10.1136/gutjnl-2015-310283Arab JP, Karpen SJ, Dawson PA, et al. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65(1):350–362. doi: 10.1002/hep.28709Arab JP, Karpen SJ, Dawson PA, et al. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65(1):350–362. doi: 10.1002/hep.28709Mazuy C, Helleboid A, Staels B, Lefebvre P. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci. 2015;72(9):1631–1650. doi: 10.1007/s00018-014-1805-yMazuy C, Helleboid A, Staels B, Lefebvre P. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci. 2015;72(9):1631–1650. doi: 10.1007/s00018-014-1805-ySinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731–744. doi: 10.1016/S0092-8674(00)00062-3Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731–744. doi: 10.1016/S0092-8674(00)00062-3Cariou B, Chetiveaux M, Zaïr Y, et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutr Metab (Lond). 2011;8(1):48. doi: 10.1186/1743-7075-8-48Cariou B, Chetiveaux M, Zaïr Y, et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutr Metab (Lond). 2011;8(1):48. doi: 10.1186/1743-7075-8-48Carr RM, Reid AE. FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease. Curr Atheroscler Rep. 2015;17(4):16. doi: 10.1007/s11883-015-0500-2Carr RM, Reid AE. FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease. Curr Atheroscler Rep. 2015;17(4):16. doi: 10.1007/s11883-015-0500-2Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103(4):1006–1011. doi: 10.1073/pnas.0506982103Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103(4):1006–1011. doi: 10.1073/pnas.0506982103Ferrebee CB, Dawson PA. Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids. Acta Pharm Sin B. 2015;5(2):129–134. doi: 10.1016/j.apsb.2015.01.001Ferrebee CB, Dawson PA. Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids. Acta Pharm Sin B. 2015;5(2):129–134. doi: 10.1016/j.apsb.2015.01.001Jahn D, Rau M, Hermanns HM, Geier A. Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine Growth Factor Rev. 2015;26(6):625–635. doi: 10.1016/j.cytogfr.2015.07.016Jahn D, Rau M, Hermanns HM, Geier A. Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine Growth Factor Rev. 2015;26(6):625–635. doi: 10.1016/j.cytogfr.2015.07.016Fuchs C, Traussnigg S, Trauner M. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2016;36(1):69–86. doi: 10.1055/s-0036-1571296Fuchs C, Traussnigg S, Trauner M. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2016;36(1):69–86. doi: 10.1055/s-0036-1571296Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3(1):5. doi: 10.3978/j.issn.2305-5839.2014.12.06Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3(1):5. doi: 10.3978/j.issn.2305-5839.2014.12.06Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113(10):1408–1418. doi: 10.1172/JCI21025Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113(10):1408–1418. doi: 10.1172/JCI21025Liu X, Xue R, Ji L, et al. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochem Biophys Res Commun. 2014;450(1):117–123. doi: 10.1016/j.bbrc.2014.05.072Liu X, Xue R, Ji L, et al. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochem Biophys Res Commun. 2014;450(1):117–123. doi: 10.1016/j.bbrc.2014.05.072Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51(2):380–388. doi: 10.1016/j.jhep.2009.03.025Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51(2):380–388. doi: 10.1016/j.jhep.2009.03.025Watanabe M, Horai Y, Houten SM, et al. Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure. J Biol Chem. 2011;286(30):26913–26920. doi: 10.1074/jbc.M111.248203Watanabe M, Horai Y, Houten SM, et al. Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure. J Biol Chem. 2011;286(30):26913–26920. doi: 10.1074/jbc.M111.248203Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2013;145(3):574–582.e1. doi: 10.1053/j.gastro.2013.05.042Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2013;145(3):574–582.e1. doi: 10.1053/j.gastro.2013.05.042Borai A, Livingstone C, Kaddam I, Ferns G. Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol. 2011;11(1):158. doi: 10.1186/1471-2288-11-158Borai A, Livingstone C, Kaddam I, Ferns G. Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol. 2011;11(1):158. doi: 10.1186/1471-2288-11-158Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965. doi: 10.1016/S0140-6736(14)61933-4Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965. doi: 10.1016/S0140-6736(14)61933-4Chiang JY. Bile Acid Metabolism and Signaling. Compr Physiol.2013;3(3):1191–1212. doi: 10.1002/cphy.c120023Chiang JY. Bile Acid Metabolism and Signaling. Compr Physiol.2013;3(3):1191–1212. doi: 10.1002/cphy.c120023Couzin-Frankel J. Lipid biology. Why high ‘good cholesterol’ can be bad news. Science 2016;351(6278):1126–1126. doi: 10.1126/science.351.6278.1126Couzin-Frankel J. Lipid biology. Why high ‘good cholesterol’ can be bad news. Science 2016;351(6278):1126–1126. doi: 10.1126/science.351.6278.1126Pencek R, Marmon T, Roth JD, et al. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes Obes Metab. 2016;18(9):936–940. doi: 10.1111/dom.12681Pencek R, Marmon T, Roth JD, et al. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes Obes Metab. 2016;18(9):936–940. doi: 10.1111/dom.12681Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015;6:10166. doi: 10.1038/ncomms10166Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015;6:10166. doi: 10.1038/ncomms10166Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125(1):386–402. doi: 10.1172/JCI76738Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125(1):386–402. doi: 10.1172/JCI76738Sayin SI, Wahlström A, Felin J, et al. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab. 2013;17(2):225–235. doi: 10.1016/j.cmet.2013.01.003Sayin SI, Wahlström A, Felin J, et al. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab. 2013;17(2):225–235. doi: 10.1016/j.cmet.2013.01.003Nie H, Song C, Wang D, et al. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR. Biochim Biophys Acta. 2017;1863(12):3087-3094. doi: 10.1016/j.bbadis.2017.09.020Nie H, Song C, Wang D, et al. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR. Biochim Biophys Acta. 2017;1863(12):3087-3094. doi: 10.1016/j.bbadis.2017.09.020Nakaoka T, Saito Y, Shimamoto Y, et al. Cluster microRNAs miR-194 and miR-215 suppress the tumorigenicity of intestinal tumor organoids. Cancer Sci. 2017;108(4):678–684. doi: 10.1111/cas.13165Nakaoka T, Saito Y, Shimamoto Y, et al. Cluster microRNAs miR-194 and miR-215 suppress the tumorigenicity of intestinal tumor organoids. Cancer Sci. 2017;108(4):678–684. doi: 10.1111/cas.13165Sundaram P, Hultine S, Smith LM, et al. p53-Responsive miR-194 Inhibits Thrombospondin-1 and Promotes Angiogenesis in Colon Cancers. Cancer Res. 2011;71(24):7490–7501. doi: 10.1158/0008-5472.CAN-11-1124Sundaram P, Hultine S, Smith LM, et al. p53-Responsive miR-194 Inhibits Thrombospondin-1 and Promotes Angiogenesis in Colon Cancers. Cancer Res. 2011;71(24):7490–7501. doi: 10.1158/0008-5472.CAN-11-1124Li P, Yang Y, Liu H, et al. MiR-194 functions as a tumor suppressor in laryngeal squamous cell carcinoma by targeting Wee1. J Hematol Oncol. 2017;10(1):32. doi: 10.1186/s13045-017-0402-6Li P, Yang Y, Liu H, et al. MiR-194 functions as a tumor suppressor in laryngeal squamous cell carcinoma by targeting Wee1. J Hematol Oncol. 2017;10(1):32. doi: 10.1186/s13045-017-0402-6Pichiorri F, Suh S-S, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development. Cancer Cell. 2010;18(4):367–381. doi: 10.1016/j.ccr.2010.09.005Pichiorri F, Suh S-S, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development. Cancer Cell. 2010;18(4):367–381. doi: 10.1016/j.ccr.2010.09.005Wang B, Shen Z, Gao Z, et al. MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle. 2015;14(7):1046–1058. doi: 10.1080/15384101.2015.1007767Wang B, Shen Z, Gao Z, et al. MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle. 2015;14(7):1046–1058. doi: 10.1080/15384101.2015.1007767Caramuta S, Egyházi S, Rodolfo M, et al. MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma. J Invest Dermatol. 2010;130(8):2062–2070. doi: 10.1038/jid.2010.63Caramuta S, Egyházi S, Rodolfo M, et al. MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma. J Invest Dermatol. 2010;130(8):2062–2070. doi: 10.1038/jid.2010.63D’Angelo E, Zanon C, Sensi F, et al. miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. Journal of J Clin Pathol. 2017:jclinpath-2017-204690. doi: 10.1136/jclinpath-2017-204690D’Angelo E, Zanon C, Sensi F, et al. miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. Journal of J Clin Pathol. 2017:jclinpath-2017-204690. doi: 10.1136/jclinpath-2017-204690Zhai H, Karaayvaz M, Dong P, et al. Prognostic significance of miR-194 in endometrial cancer. Biomark Res. 2013;(1):12. doi: 10.1186/2050-7771-1-12Zhai H, Karaayvaz M, Dong P, et al. Prognostic significance of miR-194 in endometrial cancer. Biomark Res. 2013;(1):12. doi: 10.1186/2050-7771-1-12Basati G, Razavi AE, Pakzad I, Malayeri FA. Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumour Biol. 2016;37(2):1781–1788. doi: 10.1007/s13277-015-3967-0Basati G, Razavi AE, Pakzad I, Malayeri FA. Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumour Biol. 2016;37(2):1781–1788. doi: 10.1007/s13277-015-3967-0Giaginis C, Tsoukalas N, Alexandrou P, et al. Clinical significance of farnesoid X receptor expression in thyroid neoplasia. Future Oncol. 2017;13(20):1785–1792. doi: 10.2217/fon-2017-0090Giaginis C, Tsoukalas N, Alexandrou P, et al. Clinical significance of farnesoid X receptor expression in thyroid neoplasia. Future Oncol. 2017;13(20):1785–1792. doi: 10.2217/fon-2017-0090Giaginis C, Karandrea D, Alexandrou P, et al. High Farnesoid X Receptor (FXR) expression is a strong and independent prognosticator in invasive breast carcinoma. Neoplasma. 2017;64(4):633–639. doi: 10.4149/neo_2017_420Giaginis C, Karandrea D, Alexandrou P, et al. High Farnesoid X Receptor (FXR) expression is a strong and independent prognosticator in invasive breast carcinoma. Neoplasma. 2017;64(4):633–639. doi: 10.4149/neo_2017_420You W, Chen B, Liu X, et al. Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1. Sci Rep. 2017;7(1):591. doi: 10.1038/s41598-017-00698-4You W, Chen B, Liu X, et al. Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1. Sci Rep. 2017;7(1):591. doi: 10.1038/s41598-017-00698-4

The authors declare that there are no conflicts of interest present.